Premium
Lactobacillus ingluviei C37 from chicken inhibits inflammation in LPS‐stimulated mouse macrophages
Author(s) -
Tsukagoshi Masami,
Sirisopapong Merisa,
Namai Fu,
Ishida Minori,
Okrathok Supattra,
Shigemori Suguru,
Ogita Tasuku,
Sato Takashi,
Khempaka Sutisa,
Shimosato Takeshi
Publication year - 2020
Publication title -
animal science journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.606
H-Index - 38
eISSN - 1740-0929
pISSN - 1344-3941
DOI - 10.1111/asj.13436
Subject(s) - probiotic , microbiology and biotechnology , tumor necrosis factor alpha , inflammation , lactobacillus , cytokine , biology , antibiotics , in vitro , macrophage , interleukin , bacteria , immunology , biochemistry , genetics
Probiotics are growing alternatives to antibiotics, and can contribute to the prevention and treatment of diseases and enhance livestock production. Lactobacillus ( L .) ingluviei is a novel probiotic species with growth‐enhancement effects; however, this species remains poorly understood, and there have been (to our knowledge) no studies focusing on its immunological effects. Here, we isolated L. ingluviei C37 (LIC37) from chicken and evaluated the bacterium's immunomodulatory properties to explore its probiotic potential. Real‐time quantitative PCR and ELISA showed that in vitro exposure of inflammation‐stimulated mouse peritoneal macrophages to heat‐killed LIC37 led to decreases in tumor necrosis factor‐α and interleukin (IL)‐6 levels and an increase in IL‐10. These findings suggested that LIC37 exerts anti‐inflammatory effects by modulating cytokine profiles. This species may be an attractive probiotic bacterial strain for use in animal production.